June 20, 2024Open Access

Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas

Key Points

Key points are not available for this paper at this time.

Abstract

Biomarkers reflecting real-time response to therapy and recurrence are lacking. We assessed the clinical value of detecting cell-free circulating tumor DNA (ctDNA) mutations in endometrial cancer (EC) and ovarian cancer (OC) patients.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Jamieson et al. (Thu,) studied this question.

www.synapsesocial.com/papers/68e63e32b6db6435875d049d — DOI: https://doi.org/10.3802/jgo.2025.36.e5

Authors

Amy Jamieson

Melissa K. McConechy

Amy Lum

Journals

Journal of Gynecologic Oncology

Actions

Institutions

University of British Columbia

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion